Azenta, Inc. $AZTA Shares Purchased by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC raised its stake in shares of Azenta, Inc. (NASDAQ:AZTAFree Report) by 0.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,918,366 shares of the company’s stock after purchasing an additional 2,810 shares during the period. Conestoga Capital Advisors LLC owned 4.19% of Azenta worth $59,047,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new position in Azenta during the first quarter worth approximately $505,000. Exchange Traded Concepts LLC increased its position in Azenta by 44.2% during the second quarter. Exchange Traded Concepts LLC now owns 417,597 shares of the company’s stock worth $12,854,000 after purchasing an additional 128,084 shares during the last quarter. Kera Capital Partners Inc. acquired a new position in Azenta during the second quarter worth approximately $321,000. Caxton Associates LLP acquired a new stake in shares of Azenta in the first quarter worth $1,347,000. Finally, Principal Financial Group Inc. increased its position in shares of Azenta by 2.4% in the first quarter. Principal Financial Group Inc. now owns 226,491 shares of the company’s stock worth $7,846,000 after acquiring an additional 5,408 shares in the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Price Performance

NASDAQ AZTA opened at $30.97 on Monday. Azenta, Inc. has a 12 month low of $23.91 and a 12 month high of $55.63. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -12.80 and a beta of 1.62. The company’s fifty day moving average price is $30.39 and its two-hundred day moving average price is $29.61.

Azenta (NASDAQ:AZTAGet Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The firm had revenue of $143.94 million for the quarter, compared to the consensus estimate of $149.64 million. During the same period in the prior year, the firm posted $0.14 EPS. The firm’s revenue was up .0% compared to the same quarter last year. As a group, analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Stephens assumed coverage on shares of Azenta in a research report on Tuesday, July 22nd. They issued an “equal weight” rating and a $35.00 price objective for the company. Raymond James Financial raised shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price objective for the company in a research report on Wednesday, August 6th. Evercore ISI set a $33.00 price objective on shares of Azenta and gave the stock an “in-line” rating in a research report on Tuesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Azenta in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.75.

Get Our Latest Analysis on Azenta

Azenta Profile

(Free Report)

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Recommended Stories

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.